|
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. eCollection 2016 Apr. PubMed PMID: 27141379; PubMed Central PMCID: PMC4839374.
AÑO: 2016; IF: 7.719
|
27141379
|
Periago A, Campillo JA, Mrowiec A, Gimeno L, Montes NR, Martínez-Sánchez MV, Cabañas-Perianes V, García-Garay C, Bolarin JM, Blasco-Mogorrón A, Muro M, Berenguer M, Moraleda JM, García-Alonso AM, Minguela A. Circulating aberrant plasma cells allows risk stratification of patients with myeloma. Am J Hematol. 2016 May 24. doi: 10.1002/ajh.24431. [Epub ahead of print] PubMed PMID: 27220360.
AÑO: 2016; IF: 5.275
|
|
Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Pérez-Vicente S, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Ibañez-Ruán J, Horcada L, Sánchez-Atrio A, Montilla C, Rodríguez-Gómez M, Díez-Álvarez E, Martinez-Taboada V, Andreu JL, Fernández-Berrizbeitia O, Hernández-Beriain JA, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Marras C, Bonilla G, Pego-Reigosa JM; RELESSER Study Group of the Spanish Society of Rheumatology (SER); Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S40-7. Epub 2015 Nov 17. PubMed PMID: 26575317.
AÑO: 2016; IF: 2.634
|
|
Guillamón CF, Martínez-Sánchez MV, Gimeno L, Mrowiec A, Martínez-García J, Server-Pastor G, Martínez-Escribano J, Torroba A, Ferri B, Abellán D, Campillo JA, Legaz I, López-Álvarez MR, Moya-Quiles MR, Muro M, Minguela A. NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome. Cancer Immunol Res. 2018 Dec;6(12):1537-1547. doi: 10.1158/2326-6066.CIR-18-0022. Epub 2018 Sep 21. PubMed PMID: 30242020.
AÑO: 2018; IF: 8.619
|
|
Guillamon CF, Gimeno L, Server G, Martinez-Sanchez MV, Escudero JF, Lopez-Cubillana P, Cabezas-Herrera J, Campillo JA, Abellan DJ, Martinez-Garcia J, Martinez-Escribano J, Ferri B, Lopez-Alvarez MR, Moreno-Alarcon C, Moya-Quiles MR, Muro M, Minguela A. Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers. Eur Urol Oncol. 2021 Apr;4(2):246-255. doi: 10.1016/j.euo.2019.04.009. Epub 2019 May 14. PubMed PMID: 31411976.
AÑO: 2021; IF: 8.208
|